---
title: "JP Morgan maintains Halozyme Therapeutics at Neutral, raises price target to $81 from $79"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306311142.md"
description: "JP Morgan maintained its Neutral rating on Halozyme Therapeutics, raising the price target to $81 from $79. This adjustment implies a 12.9% downside from the November 19 close of $93.04. Recent analyst actions over the past 30 days show price targets ranging from $109 to $149, with firms like HC Wainwright & Co. reiterating Buy ratings while others have downgraded or maintained their positions."
datetime: "2026-11-20T17:35:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306311142.md)
  - [en](https://longbridge.com/en/news/306311142.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306311142.md)
generator: "portal-rs"
---

# JP Morgan maintains Halozyme Therapeutics at Neutral, raises price target to $81 from $79

JP Morgan maintained Halozyme Therapeutics at Neutral and raised its price target to $81 from $79, a 2.5% increase.

The price target implies a downside of 12.9% from the Nov 19 close of $93.04.

**Recent analyst actions on Halozyme Therapeutics**

| Date   | Firm                | Action     | Rating            | Price target |
| ------ | ------------------- | ---------- | ----------------- | ------------ |
| Nov 20 | HC Wainwright & Co. | Reiterates | Buy               | $130         |
| Nov 11 | Morgan Stanley      | Downgrades | Equal-Weight      | $109         |
| Nov 6  | Leerink Partners    | Downgrades | Market Perform    | $117         |
| Nov 6  | Citizens            | Maintains  | Market Outperform | $149         |
| Nov 6  | Evercore ISI Group  | Maintains  | Outperform        | $125         |

Across the five most recent analyst notes published on Halozyme Therapeutics over the past 30 days, price targets range from $109 to $149.

Explore more price target data and ratings for Halozyme Therapeutics on the , and track all previous and future analyst recommendations in the dedicated News Flow.

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [HALO.US](https://longbridge.com/en/quote/HALO.US.md)

## Related News & Research

- [Morgan Stanley downgrades Halozyme Therapeutics to Equal-Weight from Overweight, raises price target to $109](https://longbridge.com/en/news/305201443.md)
- [Halozyme Therapeutics Director Matthew L. Posard Reports Sale of 5,000 Common Shares for $482,146.60](https://longbridge.com/en/news/306031595.md)
- [Halozyme Therapeutics President and CEO Helen Torley Reports Sale of $6 Million in Common Shares](https://longbridge.com/en/news/305745734.md)
- [Why Is Halozyme Therapeutics (HALO) Drawing Fresh Attention Today?](https://longbridge.com/en/news/305400860.md)
- [Halozyme Stock Slides, European Patent Fight With Merck Spurs Fresh Pressure](https://longbridge.com/en/news/306160621.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**